Abstract
The current prescription patterns for essential hypertension and the efficacy, safety, tolerability and cost-effectiveness of the newer antihypertensive drugs were evaluated in Nigerian patients. The findings were compared with that of a previous study conducted in the same tertiary hospital 10 years earlier. A cross-sectional evaluation of blood pressure (BP) control in a hypertension clinic was undertaken among 150 Nigerian patients aged 61±12 years (55% females), with a duration of treatment on a particular drug class or combination of 9±3 months. The initial blood pressure was 176±20/108±11 mmHg and 22% of the patient had concurrent diabetes mellitus. Thiazide diuretics (D) alone or in combination remained the most commonly prescribed drugs in 56% of all patients. There were significant increases in the prescriptions of calcium channel blockers (CCBs) (51%), P<0.0001, and ACE-inhibitors (ACEIs) (24%), P<0.0001, but a slight reduction in the use of methyldopa, and fixed drug combinations (P<0.01) compared to the previous study. The fall in systolic blood pressure on D (r=0.65, P<0.001) or CCB (r=0.48, P<0.02) was significantly correlated with the initial systolic blood pressure, but not age. More patients achieved normotension BP<140/90 mmHg on CCB monotherapy (71%), than D monotherapy (56%). Combination therapy with ACEIs+D or methyldopa+thiazides normalized BP in 63 and 68%, respectively. Pulse pressure, a surrogate marker for cardiovascular complications and mortality in essential hypertension, was significantly reduced (P<0.01) equally by all treatments, with 95% confidence intervals ranging from −28 to −1 mmHg. However, hypertensive-diabetic (HT-DM) patients (n=33) exhibited no significant change in pulse pressure in response to treatment. Adverse drug reactions that occurred in 11% were impotence or postural dizziness with D, headache and pitting oedema with CCB, and dry cough with ACEI. Pharmaco-economic comparison of the drug classes revealed that for every US dollar ($) spent per month, the percentage of treated patients attaining normotension was 18.6 for D, 4.73 for CCB, 3.5 for ACEI+D and 13.6 for methyldopa+thiazides. A combination of ACEI+CCB or D was the preferred treatment for hypertensive-diabetic Nigerians, but only 24% attained a BP<130/85 mmHg. These results demonstrate a shift in trend to a more rational and efficacious treatment of hypertension over a 10 year period. This may be associated, at least in part, with the intensive and continuous education of the prescribers in rational drug use and the introduction of a hospital formulary. Methyldopa is still a highly efficacious and cost-effective drug in this population. Black HT-DM Africans still constitute a subgroup who not only require more and costlier antihypertensive drugs, but whose BP control is suboptimal, and exhibit a poor therapeutic response to other risk factors (pulse pressure) that constitute a continuing risk for cardiovascular mortality.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akinkugbe OO . In: Hall D (ed). Hypertension in Blacks. Yearbook Publishers; Saunders, Shulman, 1985, pp 3–16.
Ajayi AA, Akinwusi PO . Spectrum of hypertensive heart disease in Nigerians: a cross-sectional study of echocardiographic indices and their correlation to treadmill exercise capacity. J Hypertens 1993; 11: 99–102.
Seedat YK . Hypertension in developing nations of sub-Saharan Africa. J Hum Hypertens 2000; 14: 739–747.
Dunn FG et al. Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indices. J Am Coll Cardiol 1983; 1: 1348.
Adigun AQ, Asiyanbola B, Ajayi AA . Cardiac autonomic function in blacks with congestive cardiac failure: vagomimetic action, alteration in sympatho-vagal balance, and the effect of ACE inhibition on central and peripheral cardiac vagal tone. Cell Mol Biol 2001; 47: 1063–1067.
Sica DA, Douglas JG . The African American Study of Kidney Disease and Hypertension. (AASK): new findings. J Clin Hypertens 2001; 3: 244–251.
Ayala C et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995–1998. Stroke 2002; 33: 1197–1201.
Seedat YK . Hypertension in black South Africans. J Hum Hypertens 1999; 13: 96–103.
Obasahan AO, Ajuyah CO . How common is heart failure due to systemic hypertension alone in hospitalized Nigerians? J Hum Hypertens 1996; 10: 801–804.
Falase AO, Ayeni O, Sekoni GA, Odia OJ . Heart failure in Nigerian hypertensives. Afr J Med Med Sci 1983; 12: 7–15.
Rotimi O, Ajayi AA, Odesanmi WO . Sudden unexpected deaths due to cardiac causes: a review of 50 autopsied series in Nigerians. Int J Cardiol 1998; 63: 111–115.
Oyewo EA, Ajayi AA, Ladipo GOA . A therapeutic audit in the management of hypertension in Nigerians. East Afr Med J 1989; 66: 458–467.
Fadayomi MO, Akinroye KK, Ajao RO, Awosika LA . Monotherapy with nifedipine for essential hypertension in adults blacks. J Cardiovasc Pharmacol 1986; 8: 466–469.
Ajayi AA, Akintomide AO . Comparison of the efficacy, safety and tolerability of amlodipine and hydrochloro-thiazide in Nigerians with essential hypertension. J Natl Med Assoc 1995; 87: 485–488.
Ajayi AA, Oyewo EA, Akinsola A, Ladipo GOA . Enalapril and hydrochlorothiazide in hypertensive Africans. Eur J Clin Pharmacol 1989; 36: 229–234.
Kolawole BA, Ajayi AA . Prognostic indices for intra-hospital mortality with non insulin dependent diabetes mellitus in Nigerians. Role of gender and hypertension. J Diabetes Complications 2000; 14: 84–89.
Celetano A et al. Relations of pulse pressure and other components of blood pressure to preclinical echo-cardiographic abnormalities. J Hypertens 2002; 20: 531–537.
Safar ME . Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr Opin Nephrol Hypertens. 2001; 10: 257–261.
Blacher J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–1089.
Guerin AP et al. Effects of antihypertensive agents on arterial pulse contour in humans. J Hum Hypertens 1992; 2 (Suppl): S37–S40.
Kawachi I . Economic factors in the initiation of antihypertensive therapy. Pharmacoeconomics 1992; 2: 324–334.
Salako BL, Kadiri S, Walker O, Fehintola FA . Evaluation of lacidipine in the treatment of hypertension in black African people: a double blind comparison with hydrochlorothiazide. Afr J Med Med Sci 1998; 27: 73–75.
Materson BJ et al. Single-drug therapy for hyper-tension in men. A comparison of six antihyper-tensive agents with placebo. The department of Veteran's Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914–921.
Hansson L et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365.
Brown MJ et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.
Nigeria profile. http://www.newAfrica.com/profile. Accessed 07/25/02.
Ajayi AA, Adigun AQ . Angioedema and cough in Nigerian patients receiving angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2000; 50: 80–82.
Sowunmi A, Rashid RJ, Akinyinka OO, Renwick AG . Ethnic differences in nifedipine kinetics: comparison of Nigerians, Caucasians, and South Asians. Br J Clin Pharmacol 1995; 40: 489–493.
Ajayi AA, Babalola RO . Enalapril and hydrochloro-thiazide combination in the treatment of hyper-tensive-diabetic Africans with proteinuria. Practical Diabetes Digest 1991; 2: 51–52.
Ajayi AA, Ajayi AT . Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease. Eur J Clin Pharmacol 1990; 39: 423–424.
Adewole AD et al. A three year clinical review of the impact of angiotensin converting enzyme inhibition on intrahospital mortality in Nigerians with congestive heart failure. Cent Afr J Med 1996; 42: 253–255.
1999 WHO/ISH guidelines for the management of hypertension. Guidelines Sub-committee. J Hypertens 1999; 17: 151–183.
Benetos A . Pulse pressure and cardiovascular risk. J Hypertens 1999; 5 (Suppl): S21–S24.
Gerdts E et al. Losartan Intervention For End (LIFE) point reduction in hypertension study. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2002; 89: 399–402.
Brown MJ et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038–1042.
Abramson JL, Weintraub WS, Vaccarino V . Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39: 197–202.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adigun, A., Ishola, D., Akintomide, A. et al. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. J Hum Hypertens 17, 277–285 (2003). https://doi.org/10.1038/sj.jhh.1001538
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001538